Explore the intricacies of prostate cancer genetic risk assessment in this 55-minute webinar presented by Ambry Genetics. Delve into the world of genome-wide association studies (GWAS) and single nucleotide polymorphisms (SNPs), understanding their role in explaining complex disease heritability. Learn about polygenic risk scores (PRS) and genetic risk scores (GRS), their calculation methods, and the importance of calibration. Discover how these tools can be used to personalize patient disease risk, with a focus on prostate cancer as a prime example. Gain insights from Dr. Brian Helfand, a board-certified urologist and Director of the Prostate Cancer Program at NorthShore University HealthSystem, as he discusses the integration of PRS with family history and rare pathogenic mutation information for comprehensive risk assessment. Explore topics such as broad-sense and narrow-sense validity, current clinical practices, and the benefits of genetic assessment in predicting risk, prognosis, and therapeutic responses for prostate cancer. Examine case examples and management strategies, providing a thorough understanding of how genetic risk assessment can be applied in clinical settings to improve patient care and outcomes. Read more